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Hepatitis C virus (HCV) is a major etiologic agent of chronic hepatitis worldwide and may lead to the development of
hepatocellular carcinoma. However, the mechanism of development of chronic hepatitis or hepatocarcinogenesis by HCV
remains unclear. In the present study, we have investigated the effect of nonstructural protein 5A (NS5A) on TNF- and
Fas-mediated apoptosis in the liver of transgenic mice. For this purpose, transgenic mice were generated by targeting the
HCV NS5A genomic region cloned under the control of a liver-specific apoE promoter. The transgenic animals were
phenotypically similar to their normal littermates and did not exhibit a detectable histological change in the liver at 8–12
weeks of age. Intraperitoneal injection of recombinant TNF induced hepatic injury and apoptosis in normal mice. In contrast,
transgenic mice expressing NS5A protein were protected against hepatic apoptosis after injection of TNF. However, injection
of anti-Fas antibody into transgenic mice did not significantly influence hepatic apoptosis compared to the normal littermates.
These results suggested distinct effects of TNF and anti-Fas antibody in transgenic mice expressing NS5A. We subsequently
investigated the effect of NS5A in signaling pathways involved in these two cytokine-mediated apoptosis. A physical
association between NS5A and TRADD was observed by pull-down assay, coimmunoprecipitation, and colocalization
experiments. Furthermore, NS5A prevented the association between TRADD and FADD and blocked TRADD-mediated NF-BINTRODUCTION
Hepatitis C virus (HCV) is a small enveloped positive-
strand RNA virus and presents as several genotypes
(Choo et al., 1989; Clarke, 1997; Simmonds, 1998; Reed
and Rice, 2000). Three to four million people in the United
States and more than 100 million people globally are
infected with this virus. HCV is not cleared easily by the
host’s immunological defense mechanism, and as many
as 85% of the people infected with HCV become chron-
ically infected (Purcell, 1994; Di Bisceglie, 1997;
Hoofnagle, 1997). The major clinical manifestation is
progressive hepatic fibrosis, which leads to cirrhosis and
an increased risk of hepatocellular carcinoma. The HCV
genome encodes a single polyprotein precursor which is
cleaved by both host and viral proteases to generate at
least 10 individual proteins. The putative structural pro-
teins (Core, E1, and E2/p7) are located in the amino-
terminal one-third of the polyprotein and the nonstruc-
tural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B)
are located in the carboxy-terminal two-thirds of the
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All rights reserved.polyprotein. HCV NS5A exists as phosphoproteins
(Kaneko et al., 1994; Ide et al., 1997; Reed et al., 1997) and
phosphorylation status also differs among the genotypes
of HCV (Hirota et al., 1999). NS5A protein has been
shown to localize in the nuclear periplasmic membrane
(Tanji et al., 1995). Recent studies have suggested that
HCV NS5A protein transcriptionally modulates cellular
genes and may promote cell growth (Gale et al., 1999;
Ghosh et al., 1999, 2000a; Majumder et al., 2001).
Apoptosis is an important biological process for the
elimination of virus-infected cells (Thompson, 1995; Na-
gata, 1997). Many viruses have evolved mechanisms
which antagonize host death signals, resulting in the
continuation of viral propagation in infected cells. Block-
ing of apoptosis could also be critical for the establish-
ment of lifelong persistence in the human host (Wang et
al., 1995; Jansen-Durr, 1996; White, 1996; O’Brien, 1998).
Apoptosis induced by TNF or Fas, the two important
components of the cellular immune defense, in virus-
infected host cells results in their elimination from the
host organism. Interruption of TNF or Fas activity can
potentially disrupt cellular defense, thereby enhancing
the likelihood of viral persistence. We have previously
reported that HCV NS5A inhibits TNF-induced apoptosis
in mammalian cells (Ghosh et al., 2000b). Transgenicactivation. Together, our results suggest that NS5A impair
transduction pathway and may play a role in HCV-mediate
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hepatitis virus-mediated pathogenesis (Milich, 2000). In
this study, transgenic mice expressing HCV NS5A in the
liver were established and the functional role of NS5A
regarding TNF- or Fas-induced apoptosis was investi-
gated. Our results suggested an inhibitory role of HCV
NS5A on TNF-mediated apoptosis, without affecting the
Fas-mediated pathway, probably by blocking the function
of the upstream signaling molecule.
RESULTS
Generation of NS5A transgenic mice
A significant obstacle in the study of HCV includes the
absence of a convenient cell culture system or a small
animal model. Advances in the field of transgenic tech-
nology offer a unique opportunity to develop rodent mod-
els for human diseases (Milich, 2000). To generate a
transgenic mouse, the HCV NS5A genomic region was
cloned under the regulatory sequence of the human
apoE gene for expression in mouse liver (Fig. 1A). Two
independent lines of transgenic mice with similar phe-
notypes were generated. Here, we have reported the
observations from transgenic mouse line L5.1, bearing
approximately two copies of the transgene determined
by Southern blot analysis (data not shown). RNA isolated
from transgenic mouse or control littermate liver was
analyzed for expression of NS5A gene by RT-PCR. The
results clearly suggested expression of NS5A-specific
sequence only in transgenic mouse lines, not in control
littermates (Fig. 1B). RNA isolated from kidney, spleen,
and lung did not exhibit NS5A expression by RT-PCR,
suggesting that the transgene expression was restricted
to the liver (Fig. 1C). NS5A-specific mRNA expression in
brain and heart from transgenic mice was not detected
from similar analysis (data not shown). NS5A protein
expression in transgenic mouse liver was confirmed by
Western blot analysis and the results suggested expres-
sion of an 56-kDa polypeptide band, while control
mouse liver failed to exhibit a detectable signal by en-
hanced chemiluminescence (Fig. 1D). Results from this
study indicated the authenticity of the transgenic mouse
line harboring an NS5A hybrid construct and the expres-
sion of the viral protein in the liver.
HCV NS5A expression in transgenic mice inhibits
TNF-mediated apoptosis
TNF is a pleiotropic cytokine and plays an important
role in viral infection. TNF is also known to be cytotoxic
in hepatocytes, specially with inhibitors of RNA synthesis
such as galactosamine (GalN) or ActD (Leist et al., 1994).
GalN is a liver-specific transcriptional blocker, which
FIG. 1. Generation of transgenic mice expressing HCV NS5A. (A) Schematic representation of pLiv7-NS5A construct. The transgenic vector contains
the human apoE regulatory region (3.0 kb) followed by an apoE intron (0.9 kb). The HCV NS5A genomic region (1.3 kb) was inserted just after the intron,
followed by the apoE poly(A) signal and a liver element (2 kb). (B) RT-PCR analysis was performed to examine the expression of NS5A in transgenic
mouse liver. A typical analysis of the PCR products by agarose gel electrophoresis from a positive-control NS5A plasmid DNA (lane 1), RNA from two
different transgenic mice (lanes 2 and 3), and RNA from a normal littermate (lane 4) is shown. (C) RT-PCR analysis showing tissue-specific NS5A
expression in liver (lane 3), kidney (lane 4), spleen (lane 5), and lung (lane 6). Results from reagent control (lane 1) and positive control (lane 2) are
also shown. (D) Protein expression by Western blot analysis is illustrated with representative liver homogenates from transgenic (lanes 1 and 2) and
normal littermates (lane 3). The molecular weight of NS5A protein band was ascertained as56 kDa from the migration of standard protein molecular
weight markers (Life Technologies, Inc.).
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depletes hepatocytes from UTP, UDP, and UMP by inter-
fering in the galactose pathways. NS5A has been re-
cently implicated for regulation of cell growth (Gale et al.,
1999; Ghosh et al., 1999, 2000a; Majumder et al., 2001).
As abnormal cell proliferation may be a consequence of
failure of programmed cell death, we examined the effect
of the NS5A expression on cytokine-induced apoptosis
of transgenic mouse liver. Histological examination was
performed in the liver of both groups of mice between the
ages of 8 and 12 weeks before TNF treatment and no
inflammation or abnormality was observed. Intraperito-
neal administration of 0.1 g recombinant mouse TNF
and 20 mg/ml GalN induced apoptosis in normal mouse
liver within 24 h (Libert et al., 1996; Van Molle et al., 1997).
We initially used a similar dose of TNF (0.1 g)/GalN to
examine whether NS5A mediates protection against
apoptosis in mouse liver. Mice were sacrificed after 24 h
of TNF treatment. Gross examination showed liver injury
in all the normal mouse liver after TNF administration.
Further analysis of DNA from normal liver exhibited frag-
mentation (6/6) as expected. In contrast, a majority of the
transgenic mice (5/6) did not exhibit apoptosis in the liver
upon TNF treatment, suggesting an in vivo protective role
of NS5A in TNF-mediated apoptosis. The results from
representative animals are shown in Fig. 2. Only one of
six normal littermates died after 16 h, while all six trans-
genic mice survived until sacrificed at 24 h after TNF
injection. The transgenic mouse showing apoptosis in
the liver is a deviation from rest of the observed results
from the remaining transgenic mice. The reason for this
is not clear and probably represents biological variation
of the observed effect. Cell death detection assay was
also employed to verify apoptosis from mouse liver ho-
mogenates, and results similar to DNA fragmentation
were obtained (Table 1). To further ensure the protective
role of NS5A in TNF-mediated apoptosis, we injected a
higher dose of TNF (0.5 g) along with GalN in both
transgenic and normal littermates. A number of normal
mice (3/6) died within 7–9 h after TNF administration. In
contrast, all six transgenic mice survived from a similar
treatment until 9 h. The surviving mice from control and
transgenic groups were sacrificed after 9 h and liver
homogenates from all mice (six in each group) were
prepared to examine the hepatic injury by cell death
detection assay (Table 1). Results suggested that the
NS5A transgenic mice were partially protected (3/6) from
apoptosis upon administration of a higher dose of TNF
(0.5 g), compared to normal littermates (6/6). The ex-
pression level of NS5A protein was examined in individ-
ual transgenic mouse livers and did not correlate with
TNF-mediated hepatic apoptosis (data not shown). Se-
rum levels of aspartate aminotransferase and alanine
aminotransferase did not significantly increase after TNF
treatment in both control and transgenic mice. Our re-
sults do not suggest a correlation of apoptosis with the
level of liver enzymes in normal littermates or transgenic
mice. In fact, chromatin fragmentation was observed
before any other sign of toxicity like fulminant liver fail-
ure. Thus, elevation of liver enzyme can be detected at
the later stage when membrane integrity is disrupted for
cytolysis, as reported earlier (Leist et al., 1994).
HCV NS5A confers an in vivo cellular resistance to
cytotoxicity from TNF
To examine the in vivo effect of NS5A following TNF
treatment, livers of cytokine-treated mice were taken for
histopathological examination. Liver from NS5A trans-
genic mice (10 weeks of age) displayed normal histology
before (Fig. 3A) and after TNF treatment (Fig. 3B). Normal
histology of liver from control mice was also observed
before cytokine treatment (Fig. 3C), while severe histo-
logical lesions, including morphological changes of typ-
ical apoptotic features and inflammation, were observed
in TNF-treated control mice (Fig. 3D), as reported earlier
(Leist et al., 1994; Libert et al., 1996; Van Molle et al.,
1997).
TABLE 1
Survival and Hepatic Apoptosis of Normal and Transgenic Mice
Following TNF Treatment
Group of micea
TNF
(g)b
Sacrificed
(h) Survival
Apoptosis
(%)c
Normal 0.1 24 5/6 100
Transgenic 0.1 24 6/6 20
Normal 0.5 9 3/6 100
Transgenic 0.5 9 6/6 50
a Six mice were included in each group.
b Indicated doses of TNF with GalN/mouse were injected intraperi-
toneally.
c Apoptosis was measured using a cell death detection assay kit
(Roche).
FIG. 2. DNA fragmentation in mouse liver following TNF treatment.
Each mouse received an intraperitoneal injection of 0.1 g of the
recombinant mouse TNF and GalN or was left as untreated control.
DNAs isolated from TNF-treated normal (lanes 1–3), untreated control
(lane 4), and TNF-treated NS5A transgenic mice (lanes 5–8) were
analyzed for genomic integrity by agarose gel electrophoresis.
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TNFR1 expression is not altered in transgenic mouse
liver
To examine whether introduction of NS5A alters the
TNFR1 expression, a semiquantitative RT-PCR analysis
was performed using RNA from the liver of transgenic
mice and their normal littermates essentially following
the same method as described earlier (Matsue et al.,
1999). GAPDH mRNA expression was similarly examined
for comparison. The PCR products from different cycles
of amplification were analyzed by agarose gel electro-
phoresis. Densitometric scanning suggested a similar
expression level of TNFR1 in transgenic mice and normal
littermates. A typical amplification profile of mRNA from
TNFR1 and GAPDH of transgenic and normal mice is
shown (Fig. 4A). Expression of TNFR1 was also exam-
ined by Western blot analysis using a specific monoclo-
nal antibody (Santa Cruz Biotechnology), and the
polypeptide band was detected by enhanced chemilumi-
nescence. A representative result shown in Fig. 4B sug-
gests similar TNFR1 expression levels. The blot when
reprobed with antibody to actin exhibited similar levels of
protein load in each lane (not shown). These results
suggested that NS5A expression in transgenic mice
does not significantly modulate TNFR1 expression. The
protein expression of TNFR1 was also examined in
HepG2 cells stably transfected with NS5A by surface
immunofluorescence using a specific monoclonal anti-
body. Both vector control and NS5A-expressing HepG2
cells displayed similar expressions of TNFR1 on the cell
surface (Fig. 4C).
Anti-Fas antibody treatment induces apoptosis in
transgenic mouse liver
Fas is an apoptosis-signaling cell surface molecule
that triggers cell death upon specific ligand or antibody
binding. Treatment of mice with an anti-Fas antibody
causes fulminant hepatic failure due to massive apopto-
sis. An intraperitoneal injection of 10–100 g of the anti-
Fas antibody (Jo2) into normal mice induces fatal liver
damage within 8 h (Ogasawara et al., 1993). To examine
the susceptibility of Fas-mediated apoptosis in normal
and NS5A transgenic mice, 10 g of Jo2 antibody was
administered intraperitoneally into each mouse. Both
normal and transgenic mice died within 9 h following
administration of the Jo2 antibody (Fig. 5A). To determine
whether Jo2 antibody induces apoptosis in liver, different
groups of normal and transgenic mice were similarly
treated with anti-Fas antibody and sacrificed after 2 or
4 h. Liver homogenates were prepared and analyzed for
apoptosis using a cell death detection assay kit. A mod-
est level of DNA fragmentation (Fig. 5B) was observed at
an early time point (2 h) in Jo2 antibody-administered
normal and transgenic mice (six in each group). How-
ever, severe apoptosis was observed in normal and
transgenic mice after 4 h of intraperitoneal administra-
tion of anti-Fas antibody (10 g). Although there was an
apparent decline in Fas-dependent apoptosis in the
transgenic mice compared to normal littermates at 4 h,
the majority of the mice from both groups (5/6) died at
similar times (Fig. 5A). To examine whether a lower dose
of Jo2 antibody could delay the apoptosis in liver, we
FIG. 3. Histopathological examination of mouse liver. Histology of livers from NS5A transgenic mice (A and B) and normal littermates (C and D) before
(A and C) and after TNF treatment (B and D). Typical features of apoptosis and inflammation were observed in TNF-treated normal littermates (D).
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injected 5 g of Jo2 antibody into normal and transgenic
mice. Both groups of mice died within 9–12 h and gross
examination of liver exhibited evidence of significant
hepatic injury. Taken together, these results suggested
that NS5A does not significantly influence the signaling
pathway of Fas-mediated apoptosis in transgenic mice.
FIG. 4. Expression of TNFR1 in transgenic mouse liver and NS5A-expressing HepG2 cells. (A) A semiquantitative RT-PCR analysis for mRNA was
performed for detection of endogenous mouse TNFR1 or GAPDH mRNA levels in normal (lanes 1–3) and transgenic (lanes 4–6) mouse liver. Analysis
of the PCR products by agarose gel from 25 cycles of amplification is shown. Data are representative of three independent RT-PCRs from each group.
(B) TNFR1 protein expression in representative mouse liver homogenate from normal (lane 1) and transgenic mouse littermates (lane 2) is shown.
The molecular weight of TNFR1 was ascertained as 55 kDa from the migration of standard protein molecular weight markers (Life Technologies,
Inc.). (C) Cell surface expression of TNFR1 in stable transfectants of HepG2 cells, with vector DNA as a control (a) and NS5A (b), is shown.
FIG. 5. Effect of anti-Fas antibody in NS5A transgenic mice. (A) Survival of mice following anti-Fas antibody treatment. Anti-Fas antibody (Jo2, 10
g/mouse) was injected intraperitoneally into six mice in each group and percentage survival at different time points is shown. (B) Cell death assay
from mouse liver homogenate following administration of anti-Fas antibody. Jo2 antibody was injected intraperitoneally into six mice of each group
and sacrificed after 2 or 4 h. DNA fragmentation using a cell death detection assay kit is presented as percentage control (as described under
Materials and Methods).
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Expression of Fas is important in triggering apoptosis
following oligomerization by the Fas ligand carried on
cytotoxic T cells (Nagata and Golstein, 1995). To examine
whether introduction of NS5A alters the Fas expression
in transgenic mice, a semiquantitative RT-PCR analysis
was performed using RNA from the liver of transgenic
mice and their normal littermates. GAPDH mRNA expres-
sion was similarly analyzed for comparison. Similar lev-
els of Fas mRNA expression in transgenic and normal
mice were observed (data not shown), suggesting NS5A
does not modulate Fas mRNA expression.
Effect of NS5A on Fas-induced apoptosis in vitro in
HepG2 cells
To further examine the in vitro effect of Fas and cor-
relation with in vivo studies, stable transfectants of
HepG2 cells expressing HCV NS5A or empty vector were
treated with anti-Fas antibody (CH-11) along with cyclo-
heximide. Anti-Fas antibody alone induces apoptotic cell
death in less than 20% of the cultured hepatocytes,
whereas complete cell death occurs within 24 h by anti-
Fas antibody in presence of cycloheximide, actinomycin
D, or PKC inhibitors (Ni et al., 1994). In our experiments,
HepG2 cells transfected with empty vector or NS5A died
within 24 h of CH-11 antibody/cycloheximide treatment
as detected by trypan blue exclusion. To investigate
whether NS5A interferes in the Fas-induced apoptotic
signaling pathway, experimental and control cell lysates
treated with CH-11 antibody/cycloheximide were immu-
noblotted with a specific antibody to caspase 3 or poly-
(ADP-ribose) polymerase (PARP). Active caspase 3 con-
sists of 17- and 12-kDa subunits which are derived
from a 32-kDa proenzyme. The caspase 3 antibody rec-
ognizes both the 32-kDa procaspase 3 and the 17-kDa
subunit protein. Activation of caspase 3 was observed in
both the experimental and the control cells (Fig. 6A).
Cleavage of the DNA repair enzyme PARP was similarly
examined. PARP cleavage from a 116-kDa protein to a
signature85-kDa fragment has been associated with a
variety of apoptotic responses, including those with ex-
posure to Fas. Vector- or NS5A-transfected HepG2 cells
displayed cleavage of the native 116-kDa PARP to its
85-kDa signature peptide after anti-Fas antibody treat-
ment (Fig. 6B). Thus, NS5A protein does not appear to
influence Fas-induced apoptosis in HepG2 cells.
HCV NS5A physically associates with TRADD
We have presented results supporting NS5A-mediated
inhibition of TNF-, but not Fas-, induced apoptosis in a
transgenic mouse model as well as by in vitro cell culture
system. In the TNF-mediated signaling pathway, TRADD
can simultaneously recruit FADD and TRAF2/RIP (Hsu et
al., 1995, 1996). We hypothesize that NS5A may interfere
with the function of TRADD in the TNF-mediated signal
transduction pathway. An in vitro binding assay was
employed to examine the physical interaction between
the viral protein NS5A and TRADD. Histidine-tagged
NS5A was expressed in bacteria (Ghosh et al., 2000a),
immobilized onto Ni-beads, and incubated with [35S]me-
thionine-labeled TRADD generated by in vitro translation.
The binding mixture was then analyzed by SDS–PAGE
followed by autoradiography. Results from the in vitro
binding assay exhibited retention of TRADD by the His-
tagged NS5A Ni-beads (Fig. 7A). However, an unrelated
cellular protein (His-MIP-2A), used as a negative control,
did not pull down the TRADD protein under similar ex-
perimental conditions. In vitro-translated FADD was also
used in the pull-down assay as a control with His-NS5A
or His-MIP-2A. NS5A and MIP-2A did not bind to FADD,
suggesting the specificity of NS5A and TRADD interac-
tion.
To further determine whether NS5A and TRADD can
form a complex in vivo, a coimmunoprecipitation assay
was performed (Fig. 7B). Coprecipitation of TRADD with
FIG. 6. Effect of NS5A on Fas-mediated procaspase 3 and PARP cleavage in HepG2 cells. Empty vector- (lanes 1 and 2) or NS5A- (lanes 3 and 4)
transfected HepG2 cells were exposed to human anti-Fas antibody (100 ng/ml) and cycloheximide (500 ng/ml) for 0 h () and 16 h ().(A) Cell lysates
were subjected to Western blot analysis using a polyclonal antibody to caspase 3. The 17-kDa band (shown by an arrow on the left) denotes the
active form of caspase 3. (B) Western blot analysis with cell lysates for PARP cleavage using a specific monoclonal antibody. An 85-kDa signature
peptide (shown by an arrow on the left) denotes the cleavage product from PARP. The molecular weight of the protein bands was ascertained from
the migration of standard protein molecular weight markers (Life Technologies, Inc).
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NS5A was evident from the specificity of the antibody
and the size of the TRADD protein (lane 1). On the other
hand, cell lysates when similarly analyzed with pooled
normal rabbit sera did not exhibit precipitation of TRADD
protein (lane 2). The level of exogenous TRADD expres-
sion from 293 cells is also shown by Western blot anal-
ysis (lane 3). However, endogenous TRADD in mock-
transfected 293 cells could not be detected (lane 4),
possibly because of a low level of TRADD expression as
observed earlier (Hsu et al., 1995). The blot when
stripped and reprobed with a specific monoclonal anti-
body to NS5A revealed viral protein (bottom).
Colocalization of NS5A with TRADD
To determine the significance of the interaction be-
tween NS5A and TRADD, we investigated whether NS5A
and TRADD colocalize in the cells. Initially, localization of
TRADD was examined by indirect immunofluorescence
using TRADD-HA-transfected 293 cells and a monoclo-
nal antibody to hemagglutinin (HA). Immunofluorescent
staining of TRADD-HA exhibited a distinct cytoplasmic
localization (Fig. 8A). Similarly, cytoplasmic localization
of NS5A was observed in CMV NS5A-transfected 293
cells (Fig. 8B). To examine colocalization of TRADD with
NS5A, 293 cells were cotransfected with CMV NS5A and
TRADD-HA. After 24 h, cells were stained together with a
mouse monoclonal antibody to HA (Fig. 8C) and a rabbit
antiserum to NS5A (Fig. 8D). Confocal microscopy sug-
gested colocalization of the TRADD with NS5A (Fig. 8E).
HCV NS5A inhibits TRADD induced NF-B activation
To investigate whether NS5A disrupts the recruitment
of TRAF2/RIP by TRADD for NF-B activation, an in vitro
transient reporter assay was performed as described
earlier (Hsu et al., 1995). 293 cells were cotransfected
with a NF-B luciferase reporter construct and TRADD
alone or with NS5A plasmid DNAs. Luciferase activity
was measured after 24 h of transfection. TRADD expres-
sion significantly increased the luciferase activity (10-
fold) as observed earlier (Hsu et al., 1995). However,
TRADD-mediated luciferase activity was inhibited in the
presence of NS5A in a dose-dependent manner (Fig. 9A).
TRADD-induced NF-B activation was not altered in the
presence of an unrelated protein (CMV MIP-2A). Similar
results were obtained with HepG2 cells in a transfection
assay. These results suggest that NS5A perturbs the
function of TRADD for the recruitment of TRAF2/RIP,
probably by interacting with TRADD.
HCV NS5A disrupts the TRADD –FADD complex
Next, we examined whether NS5A interferes with
other signaling pathways, such as TRADD–FADD asso-
ciation. For this, 293 cells were transfected with NS5A
and TRADD together or separately. Cytoplasmic extracts
were prepared after 24 h of transfection and used in a
pull-down assay with GST-FADD (a kind gift from Y. E.
Chen, Brown University, Providence, RI) followed by
Western blot analysis using an antibody to TRADD. GST-
FADD fusion protein specifically pulled down TRADD
(Fig. 9B) as recognized by TRADD antibody. However,
FADD was unable to interact with TRADD in the pres-
ence of NS5A. The blot, when reprobed with a monoclo-
nal antibody to NS5A, suggested that GST-FADD does
not bind with NS5A (data not shown), corroborating our
observations from in vitro interaction (Fig. 7A). Staining
the nitrocellulose membrane with amido black verified
the presence of similar levels of GST-FADD in each lane
(Fig. 9B, bottom). Thus, our results suggest interruption
of TRADD and FADD association by NS5A.
DISCUSSION
We have generated transgenic mice expressing the
HCV NS5A gene in the liver. NS5A has been implicated
FIG. 7. NS5A protein physically associates with TRADD. (A) In vitro-
translated [35S]methionine-labeled TRADD was subjected to pull-down
analysis with His-NS5A or His-MIP-2A (negative control) fusion protein.
In vitro-translated [35S]methionine labeled FADD was similarly sub-
jected to pull-down analysis with His-NS5A or His-MIP-2A (negative
control) fusion protein. Ten percent of the input protein (in vitro-trans-
lated TRADD or FADD) was loaded in the gel for comparison of
migration pattern. (B) In vivo coimmunoprecipitation of NS5A with
TRADD. 293 cells were cotransfected with CMV TRADD and CMV
NS5A. After 24 h of transfection, cell lysates were immunoprecipitated
with a rabbit antiserum to NS5A (lane 1) or pooled normal rabbit sera
(lane 2) and immunoblotted with a monoclonal antibody to TRADD.
Cells transfected with CMV TRADD (lane 3) and empty vector control
(lane 4) were immunoblotted with a monoclonal antibody to TRADD to
examine the exogenous expression of TRADD. The molecular weight of
the TRADD protein was ascertained from the migration of standard
protein molecular weight markers (Life Technologies). The blot was
reprobed with a monoclonal antibody for detection of NS5A (bottom).
The positions of NS5A and immunoglobulin (Ig) heavy chain (from
experimental reagents) are shown.
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in cell growth regulation and inhibition of apoptosis from
in vitro studies (Gale et al., 1999; Ghosh et al., 1999,
2000a; Majumder et al., 2001). Thus, we have utilized
these animals to study the in vivo effect of NS5A protein
expression on cytokine-mediated hepatic apoptosis.
NS5A transgenic mice were phenotypically normal and
did not exhibit liver injury at the ages of 8 to 12 weeks,
similar to their normal littermates. Results from our
present study suggest that HCV NS5A impairs TNF-
induced apoptosis in the liver of transgenic mice, sup-
porting our previous in vitro findings (Ghosh et al.,
2000b). Expression of TNFR1 in transgenic mice was
similar compared to the normal littermates. Therefore,
inhibition of TNF-mediated apoptosis in NS5A-express-
ing transgenic mice was not due to altered expression of
TNFR1. Fas-mediated cell death of hepatocytes is impli-
cated in many human liver diseases, including hepatitis
virus-related cirrhosis (Kondo et al., 1997). Fas- mediated
apoptosis of T cells plays a critical role in the control of
the immune system. Cytotoxic T lymphocytes help in the
clearance of viral infection, and perforin and Fas-based
mechanisms account for T-cell-mediated cytotoxicity
(Nagata and Golstein, 1995; Nasir et al., 2000). Here, we
have observed that hepatic apoptosis induced by anti-
Fas antibody in NS5A-expressing transgenic mice was
not significantly delayed, reduced, or enhanced com-
pared to normal littermates. Despite the fact that NS5A
did not exhibit a significant effect on Fas-mediated
apoptosis in vivo, we investigated the role of this viral
protein in the Fas-mediated signaling pathway by in vitro
studies. Similar levels of Fas-mediated apoptosis were
observed in NS5A-transfected and mock-transfected
HepG2 cells. Treatment of NS5A-expressing HepG2 cells
with anti-Fas antibody did not protect the procaspase 3
activation and PARP cleavage. Thus, our results from in
vivo and in vitro studies suggest that NS5A has no
significant effect on Fas-mediated apoptosis.
TNF- and Fas-induced apoptosis is important for lysis
of virus-infected cells. TNF is a central mediator of sys-
temic inflammatory responses and is cytotoxic to cells
infected with both DNA and RNA viruses (Mestan et al.,
1986; Wong and Goeddel, 1986). Fas is known to be
expressed in hepatocytes and its oligomerization in-
duced by agonistic Fas antibodies causes caspase ac-
tivation and apoptosis (Nagata, 1997). Fas and TNF re-
ceptor contain related cytoplasmic death domains (Itoh
and Nagata, 1993). TNFR1, after binding with ligand,
trimerizes and associates with TRADD, which then forms
a complex with FADD (Hsu et al., 1996). On the other
hand, Fas ligand binds with the Fas receptor on the cell
surface, which in turn associates directly with FADD
through its death domain. In the signaling pathway,
FADD recruits procaspase 8 to continue the apoptotic
process (Muzio et al., 1996). Our results suggest distinct
effects of TNF and anti-Fas antibody in transgenic mice
and in mammalian cells expressing NS5A. Based on the
results, we propose that NS5A may interfere with the
TNF-mediated signal transduction pathway by disrupting
the interaction between TRADD and FADD, resulting in
inhibition of apoptosis (Fig. 10). Indeed, our data demon-
strate that physical association of TRADD with NS5A
blocks the recruitment of FADD. Our results from NS5A-
mediated inhibition of TRADD-induced NF-B activation
may also account for blocking of TRADD–TRAF2/RIP
FIG. 8. Colocalization of NS5A and TRADD-HA in 293 cells. Immunofluorescent staining using specific antibody exhibits cytoplasmic localization
of TRADD-HA (A) and NS5A (B). Cells cotransfected with NS5A and TRADD were stained with a monoclonal antibody to HA for TRADD (C) and a rabbit
antibody to NS5A (D). Fluorescence images of c and d were superimposed digitally for fine comparison (E).
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interaction. NS5A may also perturb the TRADD–TNFR1
interaction, and further studies will elucidate the specific
region of TRADD as a target for NS5A protein-mediated
abrogation of TNF-induced apoptosis. HCV proteins may
employ more than one mechanisms for survival and
inhibition of apoptosis, and our results offer important
information on the role of NS5A protein in causing a
diminution of host defense mechanism and patho-
genesis.
MATERIALS AND METHODS
Plasmid construction
The plasmid CMV NS5A, containing an XhoI–EcoRI
fragment of the entire HCV NS5A region with a transla-
tional stop codon at the end, was derived from HCV-H
strain (kindly provided by R. Padmanabhan, University of
Kansas Medical Center, Kansas City, KS). The pLiv-7
vector (Allan et al., 1998) containing an apoE promoter for
expression of the liver-specific gene (kindly provided by
J. Taylor, University of California, San Francisco, CA) was
used to clone the HCV NS5A genomic region. The XhoI–
EcoRI fragment of the CMVNS5A plasmid was excised,
filled in with Klenow, and subcloned into the blunt-ended
XhoI site of the pLiv-7 vector to position the NS5A
genomic region downstream of the apoE promoter/intron
and upstream of the apoE polyadenylation sequences/
liver element. The NS5A genomic region contains the
start codon and a typical Kozak sequence. The orienta-
tion of the resulting transgene plasmid (pLiv-NS5A) was
verified by restriction enzyme digestion and nucleotide
sequence analysis of the junctions.
Microinjection and generation of NS5A transgenic
mice
A gel-purified XbaI–SpeI fragment of the apoE-intron-
NS5A-apoE polyadenylated site liver element, lacking
the vector sequences, was microinjected into fertilized
oocytes from FVB-inbred mice in the St. Louis University
Transgenic Mouse Facility. DNA isolated from individual
mouse tails was analyzed for the presence of HCV NS5A
by Southern blot hybridization (Ray et al., 1989). The tail
DNA-positive transgenic mice were first crossed with
normal mice for F1 generation, and subsequently hemi-
zygous mice were crossed for future generations. Off-
spring were screened for homozygous transgenic mice
by Southern blot analysis of tail DNA.
Analysis of transgene expression
At least two transgenic mice (one male and one fe-
male) and their normal littermates from each established
line were sacrificed at 8 weeks of age. Total RNA was
extracted separately from liver, heart, kidney, lung,
spleen, and brain using the PUREscript kit (Gentra, MN).
RT-PCR was performed using NS5A-specific sense (5-
FIG. 9. HCV NS5A inhibits TRADD-mediated signaling pathway. (A)
NF-B activation by TRADD is inhibited by NS5A. Cells (5  105)
were cotransfected with 1 g of pNF-B Luc, 0.25 g of CMV
TRADD, and/or 0.25–1 g of CMV NS5A or 1 g of CMV MIP-2A. The
total amount of DNA was kept constant by addition of empty vector.
Cells were harvested 24 h after transfection and luciferase activity
from triplicate transfections for each set of experiments is presented
as relative light units (RLU). (B) HCV NS5A blocks TRADD–FADD
interaction. 293 cells were transfected with CMV TRADD, CMV
NS5A, or both. Cell lysates were incubated with GST-FADD for
binding and detection of TRADD by Western blot analysis. The
nitrocellulose blot was stained with amido black to visualize the
expression of GST-FADD.
FIG. 10. A simplified schematic model for the role of HCV NS5A in
TNF/Fas-mediated signal transduction pathways. TNFR1 associates
with TRADD, which recruits FADD for activation of caspase and ini-
tiates the apoptotic pathway. On the other hand, the Fas receptor
directly forms complex with FADD and then activates the procaspase 8
for apoptotic signaling. TRADD also associates with TRAF2/RIP for
NF-B activation, which is inhibited by NS5A. Thus, NS5A appears to
impair TNF-mediated apoptosis, but not Fas, presumably by disrupting
the function of TRADD.
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GGACGATGAGGATCGTCGG-3) and antisense (5-TG-
GCTAGCCGAGGAGCTGG-3) primers. A calculated-size
DNA band (469 bp) was visualized by electrophoretic
analysis of the RT-PCR product on agarose gel. RT-PCR
was performed similarly for GAPDH as an internal con-
trol using specific sense and antisense primers (Ghosh
et al., 2000a). NS5A protein expression was analyzed in
livers of transgenic mice or nontransgenic control litter-
mates. Mouse liver was homogenized in RIPA buffer (0.15
M NaCl, 50 mM Tris, pH 8.0, 0.5% sodium deoxycholate,
1% NP-40, and 1% SDS), clarified by centrifugation, and
subjected to SDS–PAGE for Western blot analysis. The
blot was probed with a rabbit polyclonal antibody to HCV
NS5A (kindly provided by C. M. Rice, Washington Univer-
sity, St. Louis, MO) and the polypeptide band was de-
tected by enhanced chemiluminescence (ECL; Amer-
sham Pharmacia Biotech).
Assay for TNFR1 and Fas-receptor mRNA expression
To examine the TNF receptor 1 and Fas receptor
mRNA expression (Lewis et al., 1991; Watanabe-Fu-
nunaga et al., 1992), total RNA from normal or transgenic
mouse liver was subjected to RT-PCR using specific sets
of primers (sense 5-GGTCACTGGACTAGTCCCTT-3 and
antisense 5-GGCAGTTACACACGGTGTTCT-3 for TNFR1;
sense 5-ATGCACACTCTGCGATGAAG-3 and antisense
5-TTCAGGGTCATCCTGTCTCC-3 for Fas-receptor) as de-
scribed earlier (Matsue et al., 1999). PCR products, when
analyzed by agarose gel electrophoresis from different cy-
cles (15, 20, 25, 30, and 35), were observed to be within a
linear range of amplification. Similarly, primers for GAPDH
were used to amplify the housekeeping gene as an internal
control.
Induction of apoptosis by treatment with TNF or anti-
Fas antibody
Recombinant mouse TNF (Pharmingen; endotoxin
level 0.1 ng/g of protein) was diluted in LPS-free
phosphate-buffered saline (without Ca2 and Mg2)
along with 20 mg/ml GalN (Sigma). Anti-mouse Fas
monoclonal antibody (Jo2; Pharmingen, CA; endotoxin
level 0.01 ng/g of protein) was diluted in the same
buffer. Mice (8–12 weeks of age) were injected intra-
peritoneally (0.5 ml) with the apoptosis-inducing agent
and sacrificed at the indicated time. Mouse liver was
collected in cold perfusion buffer (50 mM phosphate
buffer, pH 7.4,120 mM NaCl, and10 mM EDTA) and a
small portion (0.5 g) was homogenized in 2 ml ice-cold
glycerol buffer (10% glycerol, 10 mM Tris/HCl, pH 7.4,
200 mM NaCl, and 5 mM EDTA) using a Dounce
homogenizer. The homogenate was centrifuged at
13,000 g for 20 min and the supernatant was stored at
80°C.
Assay for apoptosis
Cellular DNA was isolated from liver homogenate by
phenol/chloroform extraction and ethanol precipitation.
DNA prepared from mouse liver homogenate was ana-
lyzed for nucleosomal fragmentation by agarose gel
electrophoresis (Ray et al., 1998). Apoptotic cell death
was also analyzed by a cell death detection ELISA
(Roche Molecular Biochemicals, IN), which is based on
the quantitative sandwich enzyme immunoassay-princi-
ple using mouse monoclonal antibodies directed against
DNA and histone. This allows the specific determination
of mono- and oligonucleosomes in the cytoplasmic frac-
tion of cell lysates. A 96-well plate was coated with an
anti-histone antibody. Triplicate samples of the liver ho-
mogenate in glycerol buffer were added to each well. An
anti-DNA antibody conjugated to horseradish peroxidase
was used as a secondary antibody, followed by the
addition of substrate solution. The OD405 was measured
in an ELISA reader after color development. Percentage
of DNA fragmentation was compared with that of un-
treated animals and calculated as [% control  100% 
(Asample  Ablank)/(Acontrol  Ablank)].
Serum analysis
Biochemical parameters of liver enzymes in serum
(alanine aminotransferase and aspartate aminotransfer-
ase) were determined using a clinical analyzer (Roche
Cobad Mira Plus).
Histological examination
Livers from control and experimental animals were
excised and tissues immediately transferred to formalin
fixative. Samples embedded in Paraplast were sectioned
at 5 m and stained with hematoxylin and eosin. Using
light microscopy (250), 10 fields of each sample were
analyzed for apoptotic features (marked condensation of
nucleus, cell shrinkage, and apoptotic bodies).
Anti-Fas antibody treatment of HepG2 cells
expressing NS5A
HepG2 cells transfected with an empty vector (control)
or CMV NS5A (Ghosh et al., 1999) were treated with
anti-human Fas-antibody (CH-11; Medical and Biological
Laboratories, Japan) at a concentration of 100 ng/ml
along with 500 ng/ml cycloheximide (Sigma). Cells were
lysed after 16 h of anti-Fas antibody treatment and ana-
lyzed for PARP and caspase 3 cleavage. Cell lysates
were subjected to SDS–PAGE and blotted onto nitrocel-
lulose membrane. The nitrocellulose membrane was in-
cubated either with anti-caspase 3 rabbit polyclonal an-
tibody (Pharmingen) or with anti-PARP mouse monoclo-
nal antibody (Ghosh et al., 2000b), followed by
peroxidase-conjugated anti-rabbit or anti-mouse anti-
body (Bio-Rad), respectively. The polypeptide bands
were detected by ECL.
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In vitro pull-down experiment
The NS5A genomic region was cloned in frame with a
histidine-tag (His-NS5A) into the proExHTA plasmid vec-
tor (Life Technologies, Inc.) and expressed in Esche-
richia coli BL21 cells followed by immobilization onto
Ni-beads. The beads were then incubated with [35S]me-
thionine-labeled TRADD (kindly provided by D. V. Goed-
del, Tularik, Inc., CA) in vitro-translated product, and
protein complex was analyzed by SDS–polyacrylamide
gel electrophoresis, followed by autoradiography (Ghosh
et al., 2000a). In vitro-translated FADD (kindly provided by
V. M. Dixit, Genentech, CA) and His-MIP-2A (an unrelated
protein) were used as the negative controls.
Coimmunoprecipitation
Human embryonic kidney cells (293 cells) were used
in the coimmunoprecipitation assay for better transfec-
tion efficiency. Cells were cotransfected with 2 g of
CMV TRADD and 2 g of CMV NS5A plasmid DNAs, and
cell lysates were prepared after 24 h using 0.3 ml of lysis
buffer (150 mM NaCl, 10 mM HEPES, pH 7.6, 0.5% Non-
idet P-40, 5 mM EDTA) containing a cocktail of protease
inhibitors (aprotinin, leupeptin, pepstatin, and phenyl-
methylsulfonyl fluoride). Cell lysates were incubated with
a rabbit antiserum to NS5A or pooled normal rabbit sera
as a negative control for 4 h at 4°C, followed by an
overnight incubation with protein G–Sepharose beads
(Pharmacia). The immunoprecipitates were separated by
SDS–10% polyacrylamide gel electrophoresis and elec-
troblotted onto a nitrocellulose membrane. Immunoblot-
ting was performed by incubation of the membrane for
1 h with a mouse monoclonal antibody against TRADD
(Transduction Laboratory). Proteins were detected by
enhanced chemiluminescence (Amersham). The nitro-
cellulose membrane was reprobed with a monoclonal
antibody to NS5A for detection of the viral protein. To
examine the expression of exogenous TRADD, a West-
ern blot analysis was performed using TRADD- or mock-
(control) transfected cell lysates and a monoclonal anti-
body to TRADD, followed by chemiluminescence.
Immunofluorescence study
293 cells were cotransfected with CMV NS5A and
CMV TRADD-HA (a kind gift from P. Chaudhary, Univer-
sity of Texas Southwestern Medical Center, Dallas, TX) or
empty vector. After 24 h, cells were washed and fixed
with 3.7% formaldehyde followed by blocking with 3%
BSA. Cells were incubated with anti-HA mouse mono-
clonal antibody (Roche) and/or a rabbit antiserum to
NS5A for 1 h at room temperature. Cells were washed
and incubated with anti-mouse Ig conjugated with Alexa
488 and/or anti-rabbit Ig conjugated with Alexa 568 (Mo-
lecular Probes) for 30 min at room temperature. Finally,
cells were rinsed and mounted for confocal microscopy
(Bio-Rad 1024) and the images were superimposed dig-
itally to allow fine comparison (Ghosh et al., 2000a;
Majumder et al., 2001). Colocalization of red and green
signals in a single pixel produces yellow color, whereas
separated signals remain red or green. A control cell
preparation was made using only the secondary anti-
body conjugates. 293 cells expressing TRADD-HA or
NS5A were also stained with specific antibodies for
detection of proteins.
Luciferase assay
293 or HepG2 Cells (5  105) were cotransfected with
1 g of pNF-B Luc (fos minimal promoter with two
NF-B binding sites linked with the luciferase reporter
gene; kindly provided by S. Ghosh, Yale University, New
Haven, CT), 0.25 g of CMV TRADD (TRADD cDNA under
the control of CMV promoter), and/or 0.25–1 g of CMV
NS5A using Lipofectamine (Life Technologies, Inc.). The
total amount of DNA was kept constant by addition of
empty vector, and an unrelated plasmid DNA (CMV MIP-
2A) was used as a negative control. Cells were har-
vested 24 h after transfection using the reporter lysis
buffer (Promega), and luciferase activity was determined
in a luminometer (Optocomp II; MGM Instruments) as
described previously (Majumder et al., 2001). The activ-
ities were normalized with respect to the protein concen-
tration of the cell lysates.
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